Leading the way to new and better cancer treatments
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.
Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.
Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China.
Development and Manufacturing Capabilities
Polaris Group Announces Positive Top-Line Results from Phase 2/3 ATOMIC study in Patients with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin
TAIPEI, Taiwan and SAN DIEGO, Calif., September 21, 2022 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced top-line efficacy and safety data from the Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.
TAIPEI, Taiwan and SAN DIEGO, Calif., June 6, 2022 – Polaris Group (“Polaris”) (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases
Polris Group received approval from the Listing Review Committee of Taiwan Stock Exchange for Primary Listing
The Taiwan Stock Exchange Corporation held its 755th Listing Review Committee meeting on March 4, 2022 and approved the application of Polaris Group for primary …
Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology
Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and …